相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma
Bernd Heinrich et al.
GUT (2022)
Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis
Adrian T. Billeter et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2021)
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Matthias Pinter et al.
GUT (2021)
Mechanisms of nonalcoholic fatty liver disease and implications for surgery
Benedikt Kaufmann et al.
LANGENBECKS ARCHIVES OF SURGERY (2021)
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
Jessica Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) plus sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Imane H. El Dika et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma
Jason Behary et al.
NATURE COMMUNICATIONS (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma
Ruwanthi Kolamunnage-Dona et al.
JOURNAL OF HEPATOLOGY (2021)
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2021)
The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
Tomomi Kogiso et al.
CANCERS (2021)
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians
Daniel Geh et al.
HEPATOBILIARY SURGERY AND NUTRITION (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
Philipp K. Haber et al.
GASTROENTEROLOGY (2021)
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Zoe N. Memel et al.
HEPATOLOGY COMMUNICATIONS (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis
Minyoung Kwak et al.
AMERICAN JOURNAL OF SURGERY (2020)
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis
Kiichiro Ninomiya et al.
ACTA ONCOLOGICA (2020)
Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis
Shamar Young et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC
Tian Yang et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2020)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound
Hyo Jung Park et al.
JOURNAL OF HEPATOLOGY (2020)
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer
Ganessan Kichenadasse et al.
JAMA ONCOLOGY (2020)
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Tracey G. Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis
Thierry Landre et al.
DRUGS & AGING (2020)
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
Jose J. G. Marin et al.
CANCERS (2020)
Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
Claudia Campani et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma
Andrew S. Chung et al.
CANCER PREVENTION RESEARCH (2020)
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Karam Khaddour et al.
FRONTIERS IN ONCOLOGY (2020)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
Debashis Haldar et al.
JOURNAL OF HEPATOLOGY (2019)
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications
Saumya Jayakumar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization
Clemens Schotten et al.
LIVER CANCER (2019)
Diabetes Mellitus and/or Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma Showed Favorable Surgical Outcomes After Hepatectomy
Jing Liang et al.
ANTICANCER RESEARCH (2019)
Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
Ye Xin Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study
Sebastian E. Baumeister et al.
JOURNAL OF HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Comprehensive molecular and immunological characterization of hepatocellular carcinoma
Shu Shimada et al.
EBIOMEDICINE (2019)
Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients
Mehmet Artac et al.
JOURNAL OF GASTROINTESTINAL CANCER (2019)
Radiotherapy for HCC: Ready for prime time?
Andrew Bang et al.
JHEP REPORTS (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
Thomas Aparicio et al.
EUROPEAN JOURNAL OF CANCER (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The immune contexture of hepatocellular carcinoma predicts clinical outcome
Friedrich Foerster et al.
SCIENTIFIC REPORTS (2018)
Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage A Phase 2 Clinical Trial
Mary Feng et al.
JAMA ONCOLOGY (2018)
Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality A Systematic Review and Meta-Analysis
Arjun Gupta et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
Takumi Kawaguchi et al.
SCIENTIFIC REPORTS (2018)
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2018)
New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance
Michael Karin
PRECISION CLINICAL MEDICINE (2018)
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
Andrea Casadei Gardini et al.
EUROPEAN JOURNAL OF CANCER (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal et al.
GASTROENTEROLOGY (2017)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shabnam Shalapour et al.
NATURE (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization
S. E. Wu et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2017)
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period
R. Pais et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease
C. R. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes
George Cholankeril et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis
Bashar Mohamad et al.
HEPATOLOGY INTERNATIONAL (2016)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Timothy Hardy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Prospective Validation of Ab Initio Liver Transplantation in Hepatocellular Carcinoma Upon Detection of Risk Factors for Recurrence After Resection
Joana Ferrer-Fabrega et al.
HEPATOLOGY (2016)
Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study
Fabio Piscaglia et al.
HEPATOLOGY (2016)
Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis
Antonio Facciorusso et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2016)
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma et al.
NATURE (2016)
Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma
Davide Citterio et al.
JAMA SURGERY (2016)
Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis
Parissa Tabrizian et al.
ANNALS OF SURGERY (2015)
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
Arndt Weinmann et al.
BMC CANCER (2015)
Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
Rohan Chaminda Siriwardana et al.
BMC GASTROENTEROLOGY (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC
Luca Vigano et al.
JOURNAL OF HEPATOLOGY (2015)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix et al.
LANCET ONCOLOGY (2015)
Metabolic Activation of lntrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
Monika Julia Wolf et al.
CANCER CELL (2014)
Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data
Robert J. Wong et al.
CLINICAL TRANSPLANTATION (2014)
Mediterranean diet and hepatocellular carcinoma
Federica Turati et al.
JOURNAL OF HEPATOLOGY (2014)
Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome
F. Cauchy et al.
BRITISH JOURNAL OF SURGERY (2013)
Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis
Siddharth Singh et al.
GASTROENTEROLOGY (2013)
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Hsiao-Ping Chen et al.
GUT (2013)
Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
Sasan Roayaie et al.
HEPATOLOGY (2013)
Liver Transplantation for Nonalcoholic Steatohepatitis The New Epidemic
Vatche G. Agopian et al.
ANNALS OF SURGERY (2012)
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events
Lisa B. VanWagner et al.
HEPATOLOGY (2012)
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease
Srinevas K. Reddy et al.
HEPATOLOGY (2012)
Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Zhi-Jiang Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy
Lieke H. J. Simkens et al.
EUROPEAN JOURNAL OF CANCER (2011)
Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation
Tsung-Ming Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Surgical Outcomes for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
Toshifumi Wakai et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2011)
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Tae-Won Kang et al.
NATURE (2011)
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
Boris Guiu et al.
GUT (2010)
Hepatic Resection Versus Radiofrequency Ablation for Very Early Stage Hepatocellular Carcinoma: A Markov Model Analysis
Yun Ku Cho et al.
HEPATOLOGY (2010)
Lipid-induced insulin resistance: unravelling the mechanism
Varman T. Samuel et al.
LANCET (2010)
Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men
Michaela Loebig et al.
PLOS ONE (2010)
Radiofrequency Ablation of Hepatocellular Carcinoma: Long-term Results and Prognostic Factors in 235 Western Patients with Cirrhosis
Gisele N'Kontchou et al.
HEPATOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors
Young-sun Kim et al.
EUROPEAN JOURNAL OF RADIOLOGY (2006)
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T Takayama et al.
LANCET (2000)
分享论文
